Stryker Co. (NYSE:SYK) Shares Sold by Yousif Capital Management LLC

Yousif Capital Management LLC lessened its position in Stryker Co. (NYSE:SYK) by 1.7% during the fourth quarter, Holdings Channel reports. The institutional investor owned 53,858 shares of the medical technology company’s stock after selling 927 shares during the quarter. Yousif Capital Management LLC’s holdings in Stryker were worth $16,128,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of SYK. Farmers & Merchants Trust Co of Chambersburg PA grew its position in Stryker by 203.3% in the fourth quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 91 shares of the medical technology company’s stock worth $27,000 after buying an additional 61 shares during the last quarter. HBC Financial Services PLLC bought a new stake in shares of Stryker during the 4th quarter worth $37,000. Bourgeon Capital Management LLC acquired a new position in shares of Stryker in the 4th quarter worth $37,000. Operose Advisors LLC raised its position in shares of Stryker by 308.6% during the third quarter. Operose Advisors LLC now owns 143 shares of the medical technology company’s stock worth $39,000 after purchasing an additional 108 shares during the period. Finally, Venturi Wealth Management LLC lifted its holdings in shares of Stryker by 97.1% during the fourth quarter. Venturi Wealth Management LLC now owns 136 shares of the medical technology company’s stock valued at $41,000 after purchasing an additional 67 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Activity at Stryker

In related news, CAO William E. Berry, Jr. sold 7,690 shares of the company’s stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the completion of the sale, the chief accounting officer now directly owns 3,675 shares of the company’s stock, valued at approximately $1,317,414. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other news, Director Ronda E. Stryker sold 201,146 shares of the firm’s stock in a transaction on Monday, February 5th. The shares were sold at an average price of $342.90, for a total value of $68,972,963.40. Following the sale, the director now owns 3,755,128 shares in the company, valued at $1,287,633,391.20. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CAO William E. Berry, Jr. sold 7,690 shares of the company’s stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the transaction, the chief accounting officer now owns 3,675 shares of the company’s stock, valued at $1,317,414. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 212,109 shares of company stock valued at $72,845,768. Corporate insiders own 5.50% of the company’s stock.

Stryker Stock Up 0.6 %

SYK traded up $1.91 during midday trading on Wednesday, hitting $336.82. 1,023,137 shares of the company’s stock traded hands, compared to its average volume of 1,275,789. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.58 and a quick ratio of 0.97. The company has a market cap of $128.15 billion, a PE ratio of 40.85, a price-to-earnings-growth ratio of 2.64 and a beta of 0.89. Stryker Co. has a one year low of $249.98 and a one year high of $361.41. The stock’s fifty day simple moving average is $349.64 and its 200-day simple moving average is $314.08.

Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, January 30th. The medical technology company reported $3.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.27 by $0.19. The business had revenue of $5.82 billion during the quarter, compared to analyst estimates of $5.60 billion. Stryker had a net margin of 15.44% and a return on equity of 22.99%. Stryker’s quarterly revenue was up 11.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.00 EPS. As a group, equities analysts anticipate that Stryker Co. will post 11.86 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be issued a dividend of $0.80 per share. This represents a $3.20 dividend on an annualized basis and a dividend yield of 0.95%. The ex-dividend date of this dividend is Wednesday, March 27th. Stryker’s dividend payout ratio is 38.79%.

Analysts Set New Price Targets

Several research analysts have commented on SYK shares. TD Cowen raised their target price on shares of Stryker from $365.00 to $400.00 and gave the stock a “buy” rating in a report on Thursday, April 11th. Roth Mkm lifted their price objective on shares of Stryker from $345.00 to $348.00 and gave the stock a “buy” rating in a research report on Wednesday, January 31st. Citigroup increased their target price on Stryker from $362.00 to $406.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd. Truist Financial lifted their price target on Stryker from $330.00 to $345.00 and gave the company a “hold” rating in a report on Wednesday, January 31st. Finally, Canaccord Genuity Group raised Stryker from a “hold” rating to a “buy” rating and set a $360.00 price objective for the company in a research note on Wednesday, January 31st. Three equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $340.67.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.